SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

NCT02036645 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild-Moderate Alzheimer's Disease
Healthy Elderly

Interventions

BIOLOGICAL: MEDI1814 for IV injection
BIOLOGICAL: MEDI1814 for Subcutaneous Injection
BIOLOGICAL: IV Placebo
BIOLOGICAL: Placebo for Subcutaneous Injection

Sponsor

AstraZeneca